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METASTATIC RENAL CELL CARCINOMA
Jordan Dimanovski and Alek PopoviÊ
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SUMMARY · Renal cell  carcinoma is the third leading urologic cancer. Thirty percent of patients
with renal cell carcinoma have metastatic disease at the time of diagnosis. The most frequent loca-
tions of metastases from renal cell carcinoma are the lungs, mediastinum, bone, liver, and brain. There
are several treatment modifications for metastatic renal cell carcinoma, with varying results. Surgical
therapy is contraindicated in patients with multiple metastases, due to poor survival. Relief of pain
and other symptoms poses a serious problem in patients with metastases.
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Introduction
Renal cell carcinoma (RCC) is the third leading uro-
logic cancer causing approximately 7,000 deaths per year
in the United States. It is three times more common in
males than in females. Some 30% of RCC patients have
metastases at the time of primary cancer diagnosis, and
95% on autopsy1. Although some of these patients may
live relatively longer (about 10% of these patients will live
for more than 3 years), the relative survival is only 6 to 9
months2. Secondary metastases, i.e. those that occur af-
ter nephrectomy, have better prognosis than those de-
tected at the time of primary cancer diagnosis3. Metastases
develop in relatively young patients at an avarege age of
56. These metastases are often associated with pain and
other symptoms which need only palliative treatment. The
distribution and localization of RCC metastases are
shown in Tables 1 and 2 and Fig. 1.
Table 1. Frequency and distribution of renal cell carcinoma
metastases diagnosed on autopsy and at time of primary can-
cer diagnosis
Metastasis At time of On autopsy (%)
             diagnosis (%)
Multiple 97
Solitary   3
No. of organs involved
Solitary organ 70   9
Multiple organs 30 81
Fig. 1. Metastatic involvement of the ileum and the mesentery
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Table 2. Localization and frequency of renal cell carcinoma
metastases
Localization At time of diagnosis On autopsy








There are a number of therapeutic options for the
treatment of metastatic RCC with a varying success. The
main problems can be summarized in two questions: 1)
should routine radical nephrectomy be performed if me-
tastases are present?; and 2) what is the therapeutic ap-
proach to metastatic sites?
Radical Nephrectomy in Metastatic RCC
Palliative nephrectomy was for decades the procedure
of choice for metastatic RCC because it was considered
that: a) sponteneous regression of metastases would oc-
cur upon primary cancer removal; b) removal of a large
symptomatic cancer may have a significant palliative ef-
fect; and c) palliative nephrectomy could improve sur-
vival. Our experience showed these presumptions to be
too weak for routine nephrectomy in patients with meta-
static RCC.
Spontaneous postnephrectomy regression of me-
tastases occurs very rarely (in less than 0.5% of cases),
and the regression is usually transient4. In addition,
Freed et al.5 recorded regression of cancer without sur-
gical intervention in three cases. Therefore, surgery need
not be associated with spontaneous regression. The more
so, the mortality rate recorded after operative treatment
based on the patient selection criteria amounts to 2% ·
10%. Some reports suggesting the absence of metastases
after angioinfarction and subsequent nephrectomy have
yet to be proved before the procedure could be recom-
mended as a standard.
Symptom Relief
Symptom relief is a major problem in patients with
metastases. Primary cancer is rarely associated with fre-
quent or significant symptoms, and patients with multiple
metastases mostly (97%) have poor prognosis. Fifty per-
cent of them will die within 6 months. In some cases,
especially in high-risk patients, the indication for pallia-
tive nephrectomy (in symptomatic patients) can be re-
placed by selective angioinfarction (embolization).
There are little data showing that the survival of pa-
tients with distant metastases increased after ‘additional’
nephrectomy. DeKrenion and Lindner6 and Chatelain7
have demonstrated that the patients submitted to nephre-
ctomy had the same survival rate as those with metastatic
RCC.
However, some patients with metastatic RCC may
benefit from nephrectomy: 1) patients with severe symp-
toms caused by primary cancer, e.g., pain or heavy bleed-
ing, and patients who are likely to live for at least 5 months
or longer; 2) patients with solitary metastases (3% of all
cases). More than 60% of these patients will live for more
than 2 years, therefore resection of the metastasis and
nephrectomy will be a reasonable approach; and 3) the
psychological effect on the patient should also be consid-
ered as well as the patient’s desire to remove the desease.
All other indications for nephrectomy are controversial.
Maladzyz and deKernion8 studied survival in a large
number of patients with RCC and identified some con-
tributing factors: good general condition, cancer that can
be removed completely, intrarenal cancer, and metastases
confined to the lungs. A 3-year disease-free period after
‘additional’ nephrectomy is found in more than 30% of
selected patients.The same result could be achieved with-
out nephrectomy, however, implying a compromised qual-
ity of life.
Therapy for Metastases
1) Surgical excision of metastases
2) Radiotherapy
3) Systemic therapy
    · hormonal therapy
    · chemotherapy
4) Surgical excision of metastases
Local excision of metastasis as a successful therapeu-
tic option is used in patients with solitary metastases (1%
to 3% of all cases). Surgical approach is not indicated in
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Saæetak
METASTATSKI KARCINOM BUBREÆNOG PARENHIMA
J. Dimanovski i A. PopoviÊ
Karcinom bubreænog parenhima je treÊi po uËestalosti meðu urolo¹kim karcinomima. U treÊine bolesnika u trenutku
otkrivanja primarnog tumora prisutna je diseminacija bolesti. Adenokarcinom bubrega najËe¹Êe metastazira u pluÊa i u me-
dijastinum, zatim po uËestalosti slijede ko¹tane metastaze, metastaze jetre i mozga. U terapiji metastatskog adenokarcinoma
upotrebljavaju se razliËiti pristupi s promjenjivim rezultatima. Kirur¹ka terapija je kontraindicirana u bolesnika s vi¹estrukim
metastazama zbog slabog preæivljavanja. Velik problem u bolesnika s metastazama predstavlja i ublaæavaje simptoma.
KljuËne rijeËi: karcinom bubreænog parenhima, metastaze, terapija
patients with multiple metastases, because their survival
rate is low. The indications and technique of metastasis
excision depend primarily on metastasis localization.
Lung metastases are most common and are usually
removed within the healthy margin of pulmonary tissue,
whereas lobectomy or pulmectomy are rarely performed.
The best indication for surgical removal is a single me-
tastasis, however, multiple metastases can also be removed
if they are localized unilaterally.
The second most common metastases are those to the
bone. Multiple metastases have a much worse prognosis.
In some cases, the affected bone can be replaced, while in
others orthopedic fixation can be performed, sometimes
in combination with curettage of the lesion. This is mostly
performed when the patient is expected to live for the next
4 to 5 months.
In some cases, metastasis to the brain is the first sign
of the disease. Surgical operation is the first choice if the
metastasis is solid. After the operation, patients are ex-
pected to live for more than 7 months, while those with
untreated metastases have a 3-month survival at the most.
Metastases to the liver have poor prognosis, and are
usually found on autopsy. Solid liver metastases can be
treated by partial hepatectomy.
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